Incorporating brachytherapy in standard treatment protocols for elderly cervical cancer patients has the potential to improve treatment outcomes, according to a review study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
Stratifying ovarian cancer patients with gene expression molecular subtypes (GEMS) enables the identification of AXL in mesenchymal subtype ovarian cancer, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
Monotherapy using the immune checkpoint inhibitors anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may not be sufficient for ovarian cancer, according to data presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
Chemotherapy is associated with better overall survival (OS) in patients with advanced angiosarcoma, though only a select number receive this treatment, according to findings from the first collaborative study by the Asian Sarcoma Consortium (ASC).
Nivolumab has emerged as a potential therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based therapy, based on results of a subgroup analysis of Asian patients in the CheckMate 141* trial.
Palbociclib, in combination with letrozole, significantly improves progression-free survival (PFS) in Asian postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer compared with letrozole alone, according to a sub-analysis of Asian patients enrolled in the PALOMA-2* study presented at the recent European Society for Medical Oncology Asia 2016 Congress (ESMO Asia 2016) in Singapore.
Ceritinib shows clinically meaningful activity in advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), producing a rapid, durable response rate and improvements in patient-reported outcomes in individuals who have progressed on crizotinib, according to two studies presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
During the period between 1999 and 2008, there have been major changes in the preferences of breast cancer treatment in China, according to an expert who spoke at the recently concluded European Society of Medical Oncology (ESMO) Asia 2016 Congress.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.